Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Canadian Provinces Launch $3M Drug-Enabling Tech Initiative

By Drug Discovery Trends Editor | November 5, 2013

Ontario Centres of Excellence (OCE) and the Québec Consortium for Drug Discovery (CQDM) are teaming up with Life Sciences Ontario and BiopolisQuébec to advance pharmaceutical research in the two provinces.
Having established a working partnership through the two-year-old Ontario-Québec Life Sciences Corridor initiative, OCE and CQDM are leading the $3 million inter-provincial “OCE-CQDM Life Sciences R&D Challenge” supporting industry-academic collaborations that will result in innovative tools and technologies to improve and accelerate the drug discovery process.
“This initiative will help build a competitive advantage for the sector in both provinces by combining resources and strengths across the Ontario-Québec Life Sciences Corridor,” said Tom Corr, president and CEO of OCE. “This will not only help lead to new products but pave the way for new and unique opportunities for investments, partnerships and collaborations.”
The initiative was announced by Reza Moridi, Ontario’s Minister of Research and Innovation, on Oct. 29 at OCE’s Annual General meeting and is funded in part by Ontario’s Collaboration Voucher program.
“This new industry voucher is an important step in advancing pharmaceutical research,” said Minister Moridi. “It builds on the working relationship we’ve established through the Ontario-Québec Life Sciences Corridor. And it fulfills the kind of collaborative partnerships we envisioned when the corridor was created in 2011.”
Through this challenge, OCE and CQDM will support up to four qualified projects (lasting up to three years) that undertake biopharmaceutical research leading to improvements in drug discovery technologies. The challenge is not funding new drug discovery, rather the development of cutting-edge technologies with strong and immediate impact on drug discovery.
OCE and CQDM will each provide $125,000-$150,000 per project (up to $500,000 each in total) with industry partners contributing another $500,000-$600,000 per project (up to $2 million in total).
As industry association partners, Life Sciences Ontario and BiopolisQuébec will promote the challenge to their members and engage in outreach to drive awareness and collaboration and host an industry-academic partnering forum on Nov. 28 to solicit project proposals and to provide a networking opportunity for potential collaborators.
“We strongly believe that this newly launched program will build powerful private/public relationships across the Ontario-Québec Life Sciences Corridor” said Diane Gosselin, president and CEO at CQDM.  “This program launch is in-line with our believe that partnerships are essential to support disruptive technology that really will make a difference in delivering cost effective, safe and  innovative-based medications to patients.”
“It is with great pleasure that the Québec government reiterates its support for sectoral clusters of industrial research in our new National Policy on research and innovation. We have put in place effective measures to bring together our respective advantages in the area of research. We are happy and proud to see that much networking between Québec and Ontario researchers”, said Pierre Duchesne, Québec’s Minister of Higher Education, Research, Science and Technology.
“This is a terrific collaboration that will benefit life sciences companies and researchers across both provinces.” said Jason Field, executive director of Life Sciences Ontario. “Since signing the MOU between LSO and BiopolisQuébec in 2012, we have forged a strong relationship with our partners in Québec. This announcement is a testament to this partnership and a significant step in the evolution of the Ontario-Québec Life Sciences Corridor.”
“BiopolisQuébec is pleased that the agreement signed with LSO in 2012 to support the Ontario-Québec Life Sciences Corridor is paying off. The partnership between CQDM and OCE will help promote co-operation between companies and institutions in both provinces and showcase them to the rest of the world,” says Josée Fortin, director general at Sherbrooke Innopole, a member of the BiopolisQuébec alliance.
Date: October 30, 2013
Source: Ontario Centres of Excellence (OCE)

Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE